Lexicon Appoints Mike Exton As New Chief Executive Officer And Director Succeeding Lonnel Coats Who, As Previously Announced, Retired Effective July 7, 2024
$LXRX
Biotechnology: Pharmaceutical Preparations
Health Care
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis.